Xilis

Xilis develops advanced patient-derived organoid technology to accelerate pharmaceutical development and improve cancer treatment outcomes. The company's proprietary MicroOrganoSphere® (MOS) platform creates 3D micro-tumor models that preserve the cellular composition, genetic alterations, immune microenvironment, and histopathology of primary patient tissue. These models enable more accurate drug efficacy predictions and reduce risk throughout the drug discovery and development lifecycle—from initial discovery through clinical trials—spanning immuno-oncology, chemotherapy, and cell therapy applications. The platform integrates automated model creation, customizable assays, and AI-powered analytics to support both precision oncology diagnostics and pharmaceutical R&D partnerships.